AtCor's pressure rises
Wednesday, 30 July, 2008
AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.
This represents a 47 per cent increase over last year's sales.
The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.
The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.
Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
